Exceptional GMP flexibilities for medicines imported from third countries during the coronavirus (COVID-19) outbreak

AI Summary

This guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) outlines exceptional flexibilities for medicine distribution and manufacturing during the COVID-19 pandemic. Operating under the GMP Annex 16 regulatory framework, the document allows Qualified Persons (QPs) to use professional judgment regarding minor deviations in product specifications and analytical methods, provided safety and efficacy are maintained. To prevent supply chain delays, the MHRA permits reduced re-testing for imported products. Medicines from PIC/S countries may bypass re-testing if fully tested at the source, while those from non-PIC/S territories may undergo limited testing, such as identity and assay. Biological products, however, still require full specialist analysis. Companies implementing these flexibilities must take specific actions: decisions must be recorded in the pharmaceutical quality system, and the MHRA must be notified via a dedicated email address. Additionally, firms must maintain transparency by informing supply chain partners and notifying other relevant European authorities if products are marketed outside the UK. These measures are designed to ensure the continuous supply of critical medicines while protecting public health through a risk-based approach to quality oversight.